
News|Videos|August 29, 2025
Lessons from Psoriasis Action Month: Insights from Three Patient Journeys
Author(s)Lana Pine
Multidisciplinary management and patient-centered care are critical for optimizing outcomes in complex or severe psoriasis cases.
Advertisement
Advertisement
As part of Psoriasis Action Month, patient narratives reveal the complex interplay between disease severity, comorbidities, and psychosocial burden in psoriasis management. Cases like those of Ayesha Patrick, Brian Lehrschall, and Janene Tirado illustrate the heterogeneity of psoriasis, spanning common chronic plaque forms, rare pustular variants, and the compounded impact of multimorbidity. These stories underscore the importance of timely diagnosis, culturally competent care, and multidisciplinary management in optimizing outcomes.
Related to this article

From a pediatric alopecia areata approval to head-to-head TYK2 data at EADV, here are 7 dermatology stories from September 2026.

Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.

Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.

Late-breaking EADV data show TNFα and OX40L localize near HS draining tunnels as Navigator Medicines advances its dual-targeting bispecific antibodies.

Thomas Casale, MD, discusses pooled CUPID A and C data showing dupilumab improved quality of life in omalizumab-naive chronic spontaneous urticaria.

In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.

An indirect comparison finds higher placebo-adjusted skin and itch responses with upadacitinib vs nemolizumab in atopic dermatitis.
Advertisement
Advertisement

